Spinraza’s Approval Brings Promise — and Challenges — for SMA Treatment, Review Says
Approval of Spinraza (nusinersen), the first disease-modifying therapy for spinal muscular atrophy (SMA), has brought not only hope, but also some challenges for both patients and researchers, according to a recent review. The study, “Advances in therapy for spinal muscular atrophy: promises and challenges,” was published…